JP2002500181A - ジスキネジーの処置 - Google Patents
ジスキネジーの処置Info
- Publication number
- JP2002500181A JP2002500181A JP2000527236A JP2000527236A JP2002500181A JP 2002500181 A JP2002500181 A JP 2002500181A JP 2000527236 A JP2000527236 A JP 2000527236A JP 2000527236 A JP2000527236 A JP 2000527236A JP 2002500181 A JP2002500181 A JP 2002500181A
- Authority
- JP
- Japan
- Prior art keywords
- riluzole
- dyskinesia
- levodopa
- pharmaceutical composition
- per day
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 208000012661 Dyskinesia Diseases 0.000 title claims abstract description 51
- 238000011282 treatment Methods 0.000 title claims description 16
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 claims abstract description 33
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 claims abstract description 33
- 229960004502 levodopa Drugs 0.000 claims abstract description 33
- FTALBRSUTCGOEG-UHFFFAOYSA-N Riluzole Chemical compound C1=C(OC(F)(F)F)C=C2SC(N)=NC2=C1 FTALBRSUTCGOEG-UHFFFAOYSA-N 0.000 claims abstract description 30
- 229960004181 riluzole Drugs 0.000 claims abstract description 28
- 206010043118 Tardive Dyskinesia Diseases 0.000 claims abstract description 12
- 239000008194 pharmaceutical composition Substances 0.000 claims description 13
- 238000000034 method Methods 0.000 claims description 8
- 239000002552 dosage form Substances 0.000 claims description 7
- 239000004480 active ingredient Substances 0.000 claims description 3
- 230000000561 anti-psychotic effect Effects 0.000 claims description 2
- 230000001668 ameliorated effect Effects 0.000 abstract 1
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 16
- 208000018737 Parkinson disease Diseases 0.000 description 13
- 229960003638 dopamine Drugs 0.000 description 8
- 230000003291 dopaminomimetic effect Effects 0.000 description 7
- 230000017311 musculoskeletal movement, spinal reflex action Effects 0.000 description 7
- 201000010099 disease Diseases 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 208000024891 symptom Diseases 0.000 description 6
- 208000015592 Involuntary movements Diseases 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 238000011156 evaluation Methods 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 239000003176 neuroleptic agent Substances 0.000 description 5
- 230000000701 neuroleptic effect Effects 0.000 description 5
- 210000003523 substantia nigra Anatomy 0.000 description 5
- 230000001684 chronic effect Effects 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 238000009534 blood test Methods 0.000 description 3
- 239000003136 dopamine receptor stimulating agent Substances 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 230000000750 progressive effect Effects 0.000 description 3
- 206010008748 Chorea Diseases 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 239000000939 antiparkinson agent Substances 0.000 description 2
- 239000000164 antipsychotic agent Substances 0.000 description 2
- 229940005529 antipsychotics Drugs 0.000 description 2
- 210000004227 basal ganglia Anatomy 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 208000012601 choreatic disease Diseases 0.000 description 2
- 230000007850 degeneration Effects 0.000 description 2
- 229940052760 dopamine agonists Drugs 0.000 description 2
- 210000005064 dopaminergic neuron Anatomy 0.000 description 2
- 230000000142 dyskinetic effect Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 210000001640 nerve ending Anatomy 0.000 description 2
- 230000004770 neurodegeneration Effects 0.000 description 2
- 208000015122 neurodegenerative disease Diseases 0.000 description 2
- 230000000926 neurological effect Effects 0.000 description 2
- 238000007427 paired t-test Methods 0.000 description 2
- 230000001144 postural effect Effects 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- WBLZUCOIBUDNBV-UHFFFAOYSA-N 3-nitropropanoic acid Chemical compound OC(=O)CC[N+]([O-])=O WBLZUCOIBUDNBV-UHFFFAOYSA-N 0.000 description 1
- 241001573498 Compacta Species 0.000 description 1
- 229940123736 Decarboxylase inhibitor Drugs 0.000 description 1
- 101000879758 Homo sapiens Sjoegren syndrome nuclear autoantigen 1 Proteins 0.000 description 1
- 208000023105 Huntington disease Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 208000003367 Hypopigmentation Diseases 0.000 description 1
- 102000010909 Monoamine Oxidase Human genes 0.000 description 1
- 108010062431 Monoamine oxidase Proteins 0.000 description 1
- 241000282520 Papio Species 0.000 description 1
- 206010071390 Resting tremor Diseases 0.000 description 1
- 208000034189 Sclerosis Diseases 0.000 description 1
- 102100037330 Sjoegren syndrome nuclear autoantigen 1 Human genes 0.000 description 1
- 206010044565 Tremor Diseases 0.000 description 1
- 208000024453 abnormal involuntary movement Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000002253 anti-ischaemic effect Effects 0.000 description 1
- 230000000648 anti-parkinson Effects 0.000 description 1
- 229940035678 anti-parkinson drug Drugs 0.000 description 1
- 230000002921 anti-spasmodic effect Effects 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 238000004820 blood count Methods 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000003467 cheek Anatomy 0.000 description 1
- 239000000812 cholinergic antagonist Substances 0.000 description 1
- 238000009535 clinical urine test Methods 0.000 description 1
- 239000003954 decarboxylase inhibitor Substances 0.000 description 1
- 238000006114 decarboxylation reaction Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000009433 disease-worsening effect Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 210000000744 eyelid Anatomy 0.000 description 1
- 210000001097 facial muscle Anatomy 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000003425 hypopigmentation Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 210000004558 lewy body Anatomy 0.000 description 1
- 210000000088 lip Anatomy 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000037023 motor activity Effects 0.000 description 1
- 230000007659 motor function Effects 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- 210000001577 neostriatum Anatomy 0.000 description 1
- 230000000324 neuroprotective effect Effects 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 229940052740 other dopaminergic agent in atc Drugs 0.000 description 1
- 238000011458 pharmacological treatment Methods 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000003518 presynaptic effect Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 210000003019 respiratory muscle Anatomy 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 210000000225 synapse Anatomy 0.000 description 1
- 230000000946 synaptic effect Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 210000002105 tongue Anatomy 0.000 description 1
- 210000001364 upper extremity Anatomy 0.000 description 1
- 230000002618 waking effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/428—Thiazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Thiazole And Isothizaole Compounds (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IL12288398A IL122883A0 (en) | 1998-01-09 | 1998-01-09 | Pharmaceutical compositions for the treatment of dyskinesias |
| IL122883 | 1998-01-09 | ||
| IL127102 | 1998-11-17 | ||
| IL12710298A IL127102A0 (en) | 1998-11-17 | 1998-11-17 | Pharmaceutical compositions for the treatment of dyskinesias |
| PCT/IL1999/000003 WO1999034785A2 (en) | 1998-01-09 | 1999-01-05 | Treatment of dyskinesias |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2002500181A true JP2002500181A (ja) | 2002-01-08 |
| JP2002500181A5 JP2002500181A5 (enExample) | 2006-03-02 |
Family
ID=26323572
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000527236A Pending JP2002500181A (ja) | 1998-01-09 | 1999-01-05 | ジスキネジーの処置 |
Country Status (10)
| Country | Link |
|---|---|
| EP (1) | EP1043996A2 (enExample) |
| JP (1) | JP2002500181A (enExample) |
| KR (1) | KR20010033978A (enExample) |
| CN (1) | CN1290166A (enExample) |
| AU (1) | AU1780699A (enExample) |
| BR (1) | BR9906821A (enExample) |
| CA (1) | CA2317811A1 (enExample) |
| NO (1) | NO20003529L (enExample) |
| PL (1) | PL342098A1 (enExample) |
| WO (1) | WO1999034785A2 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2790670A1 (fr) * | 1999-03-12 | 2000-09-15 | Aventis Pharma Sa | Association riluzole et antagoniste des recepteurs ampa |
| JP2002539162A (ja) * | 1999-03-12 | 2002-11-19 | アベンテイス・フアルマ・ソシエテ・アノニム | リルゾールおよびａｍｐａ受容体アンタゴニストの組み合わせ剤を用いる筋萎縮性側索硬化症の治療 |
| FR2801793B1 (fr) * | 1999-12-01 | 2003-07-04 | Aventis Pharma Sa | Association d'une ergoline et de riluzole et son utilisation comme medicament |
| US6297254B1 (en) | 1999-12-01 | 2001-10-02 | Aventis Pharma S. A. | Method for the prevention or treatment of a motoneuron disease |
| FR2809620B1 (fr) * | 2000-06-05 | 2002-08-02 | Aventis Pharma Sa | Utilisation du riluzole ou ses sels pour la prevention et le traitement de l'adrenoleucodystrophie |
| ATE246919T1 (de) * | 2001-05-08 | 2003-08-15 | Sanol Arznei Schwarz Gmbh | Verbessertes transdermales therapeutisches system zur behandlung von morbus parkinson |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2688138B1 (fr) * | 1992-03-06 | 1995-05-05 | Rhone Poulenc Rorer Sa | Application de l'amino-2 trifluoromethoxy-6 benzothiazole pour obtenir un medicament destine au traitement de la sclerose laterale amyotrophique. |
| FR2700117B1 (fr) * | 1993-01-07 | 1995-02-03 | Rhone Poulenc Rorer Sa | Application d'anticonvulsivants dans le traitement de la maladie de Parkinson et des syndromes parkinsoniens. |
-
1999
- 1999-01-05 WO PCT/IL1999/000003 patent/WO1999034785A2/en not_active Ceased
- 1999-01-05 PL PL99342098A patent/PL342098A1/xx unknown
- 1999-01-05 KR KR1020007007567A patent/KR20010033978A/ko not_active Withdrawn
- 1999-01-05 JP JP2000527236A patent/JP2002500181A/ja active Pending
- 1999-01-05 EP EP99900116A patent/EP1043996A2/en not_active Withdrawn
- 1999-01-05 CN CN99802790A patent/CN1290166A/zh active Pending
- 1999-01-05 BR BR9906821-4A patent/BR9906821A/pt not_active IP Right Cessation
- 1999-01-05 AU AU17806/99A patent/AU1780699A/en not_active Abandoned
- 1999-01-05 CA CA002317811A patent/CA2317811A1/en not_active Abandoned
-
2000
- 2000-07-07 NO NO20003529A patent/NO20003529L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| BR9906821A (pt) | 2000-10-17 |
| WO1999034785A2 (en) | 1999-07-15 |
| EP1043996A2 (en) | 2000-10-18 |
| NO20003529L (no) | 2000-09-08 |
| CN1290166A (zh) | 2001-04-04 |
| NO20003529D0 (no) | 2000-07-07 |
| AU1780699A (en) | 1999-07-26 |
| WO1999034785A3 (en) | 1999-09-16 |
| CA2317811A1 (en) | 1999-07-15 |
| KR20010033978A (ko) | 2001-04-25 |
| PL342098A1 (en) | 2001-05-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7650929B2 (ja) | 成人における焦点てんかんの処置のための合成経皮的カンナビジオール | |
| US10980759B2 (en) | Treatment of nervous system disorders using combinations of RXR agonists and thyroid hormones | |
| JP4097285B2 (ja) | 種々の頑固な疾患の治療のための医薬の製造に有用な組成物 | |
| US20040029941A1 (en) | Zonisamide use in obesity and eating disorders | |
| KR20070085838A (ko) | 운동 장애의 치료 방법 | |
| EA002554B1 (ru) | Применение кабэрголина при лечении синдрома усталых ног | |
| EP1435943B1 (en) | Use of 2-oxo-1-pyrrolidine derivatives for the preparation of a drug for treating dyskinesia | |
| EP1737438B1 (en) | Alpha-aminoamide derivatives useful in the treatment of restless legs syndrome | |
| JP2002509104A (ja) | 遅発性ジスキネジア及び他の運動障害の治療方法 | |
| JPS59193821A (ja) | 抗不安薬としてのフルオキセチンの使用法 | |
| Playfer | Parkinson's disease | |
| JP2003530349A (ja) | 皮膚病用の使用方法及び皮膚病用薬剤 | |
| JP2002500181A (ja) | ジスキネジーの処置 | |
| US6417210B1 (en) | Treatment of dyskinesias and Parkinson's disease with riluzole and levodopa | |
| JPH05505817A (ja) | 勃起不能を処理するためのミノキシジルの使用 | |
| TW202237103A (zh) | 用於治療抑鬱症的ｎｒ２ｂ－ｎｍｄａ受體ｎａｍ之劑量方案 | |
| DE60125062T2 (de) | Quetiapin zur Behandlung der Dyskinesie in nicht-psychotischen Patienten | |
| JPH0276813A (ja) | 神経変性疾患の治療薬 | |
| JP2003512428A (ja) | ジスキネジーの治療 | |
| JP2001526217A (ja) | 血管性頭痛に対する局所麻酔薬の新規な使用 | |
| Torri et al. | (409) A Double-Blind, Placebo-Controlled, Phase 2 Study to Assess the Safety and Efficacy of NYX-2925 in Subjects with Painful Diabetic Peripheral Neuropathy | |
| MXPA00006800A (en) | Treatment of dyskinesias | |
| WO2004105756A2 (en) | Combination comprising (a) a neuroprotecting agent and (b) an agent binding to gadph and pharmaceutical use thereof | |
| WO1993016696A1 (en) | Brofaromine as an agent for treating social phobia | |
| JPH08504436A (ja) | 血液循環を改善するための４−グアニジノブチルアミド |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20060104 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20060104 |
|
| RD02 | Notification of acceptance of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7422 Effective date: 20090116 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20090811 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20100202 |